RxDoctor Payments Data

Andrea Moyer, MD

Cardiovascular Disease · Chesterfield, MONPI 1659318996

Payments from drug & device makers

$807in general payments, 2019–2025

Across 43 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$107
  • Boston Scientific$101
  • Boehringer Ingelheim$80
  • Abbott$65
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$64
  • Regeneron Healthcare Solutions, Inc.$58
  • plus $332 from 11 others

What the payments were for

  • Consulting fees$395%
  • Food & beverage$76895%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$807 in reported general payments places this provider in the 30th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$146,964
Medicare patients
1,028
Services billed
2,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban512$554,156
EntrestoSacubitril/Valsartan230$245,108
JardianceEmpagliflozin184$158,304
XareltoRivaroxaban61$68,584
FarxigaDapagliflozin Propanediol42$41,598
Repatha SureclickEvolocumab34$23,635
BrilintaTicagrelor29$17,830
Dabigatran EtexilateDabigatran Etexilate Mesylate68$14,942
Amiodarone Hcl134$4,972
Dofetilide22$4,594
Metoprolol Succinate442$4,114
Midodrine Hcl26$2,591
Diltiazem 24hr Er (Cd)Diltiazem Hcl89$2,522
Valsartan104$2,178
Atorvastatin Calcium324$1,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$554,156512 claims
NovartisEntresto$57$245,108230 claims
Boehringer IngelheimJardiance$80$158,304184 claims
Johnson & JohnsonXarelto$38$68,58461 claims
AstraZenecaFarxiga, Brilinta$16$59,42871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →